Uterine Cancer Treatment in India
Get Uterine Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Uterine Cancer Treatment in UAE
Uterine Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Uterine (endometrial) cancer treatment encompasses a multidisciplinary spectrum of care — from robotic-assisted radical hysterectomy and sentinel lymph node mapping to platinum-based chemotherapy, external beam radiation therapy (EBRT), and targeted biologics such as pembrolizumab and lenvatinib. With stage-specific five-year survival rates ranging from 95% for localized disease to approximately 17% for metastatic disease, early and expert intervention is critical. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centres in India and JCI- and DHA-licensed facilities in Dubai and Abu Dhabi, offering world-class gynecologic oncology at a fraction of Western costs, with end-to-end concierge support from first consultation through discharge and follow-up.
Hospital Stay: 5–10 days (varies by modality: 3–5 days for minimally invasive surgery; longer for open surgery or combined chemoradiation admission) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (robotic/laparoscopic surgery: ~3 weeks; open radical hysterectomy or concurrent chemoradiation: 5–6 weeks; medical clearance and DVT risk assessment required before boarding) • Success Rate: Stage I: ~95% | Stage II: ~70% | Stage III: ~40–50% | Stage IV: ~15–20% (5-year overall survival; highly stage- and histology-dependent)
What Is It?
Uterine cancer — the most common gynecologic malignancy in developed nations — arises predominantly from the endometrial lining (endometrial carcinoma, ~90% of cases) or, less commonly, from the uterine musculature (uterine sarcoma, including leiomyosarcoma and carcinosarcoma). Endometrial carcinoma is histologically classified into Type I (estrogen-driven, endometrioid adenocarcinoma, typically low-grade and confined to the uterus at diagnosis) and Type II (non-estrogen-driven, including serous, clear cell, and undifferentiated carcinomas, which carry a more aggressive biological course). Molecular subtyping per The Cancer Genome Atlas (TCGA) framework — POLE ultra-mutated, mismatch repair deficient (MMRd/MSI-H), copy-number low, and copy-number high (p53-mutant serous-like) — now directly informs adjuvant therapy decisions and immunotherapy eligibility.
Physiologically, the disease disrupts the endocrine-reproductive axis and, in advanced stages, compromises bladder, bowel, and vascular structures through direct extension or nodal spread via the iliac and para-aortic lymphatic chains. Paraneoplastic manifestations are uncommon but include hypercalcemia in serous subtypes. Diagnosis is confirmed via transvaginal ultrasound (endometrial thickness >4 mm in postmenopausal women is the accepted threshold for investigation), office endometrial biopsy, or hysteroscopy with directed biopsy. MRI pelvis with contrast remains the gold-standard for local staging, while PET-CT is deployed for nodal and distant metastasis assessment in high-grade or advanced disease.
The contemporary standard of care is governed by FIGO 2023 surgical staging guidelines and ESGO/ESTRO/ESP consensus recommendations. For early-stage disease, minimally invasive total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) and sentinel lymph node (SLN) biopsy using indocyanine green (ICG) near-infrared fluorescence mapping has largely supplanted full pelvic lymphadenectomy, reducing lymphedema morbidity without compromising oncologic outcomes. Adjuvant therapy — vaginal brachytherapy, EBRT, carboplatin/paclitaxel chemotherapy, or the addition of pembrolizumab (for MMRd tumors, per KEYNOTE-868 data) — is risk-stratified using the ESMO-ESGO-ESTRO classification (low, intermediate, high-intermediate, high, and advanced/metastatic risk groups).
Candidates
• ELIGIBLE PATIENTS:
• Postmenopausal women with confirmed endometrial biopsy or hysteroscopic biopsy showing endometrial carcinoma or uterine sarcoma at any FIGO stage
• Premenopausal women with histologically confirmed diagnosis who are not candidates for fertility-sparing management
• Patients with FIGO Stage IA Grade 1–2 endometrioid carcinoma seeking fertility-sparing hormonal therapy (high-dose progestins + levonorgestrel IUD) — strictly under specialist guidance and with mandatory follow-up biopsies
• Patients with recurrent or metastatic disease requiring systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
• Patients with Lynch syndrome or hereditary endometrial cancer requiring prophylactic or therapeutic surgical intervention
• REQUIRED PRE-TREATMENT DIAGNOSTICS:
• Endometrial biopsy (Pipelle) or hysteroscopy-directed biopsy for histological confirmation and grade assignment
• Immunohistochemistry (IHC) panel: MMR proteins (MLH1, MSH2, MSH6, PMS2), p53, ER/PR, and L1CAM
• Molecular profiling: POLE mutation testing, MSI-H/dMMR by PCR or next-generation sequencing (NGS)
• MRI pelvis with contrast (3T preferred) for myometrial invasion depth and cervical stromal involvement
• PET-CT (18F-FDG) for FIGO Stage II–IV, high-grade histology, or suspected nodal/distant metastasis
• Transvaginal ultrasound if MRI is contraindicated
• Complete blood count, comprehensive metabolic panel, CA-125 (useful in serous subtype for monitoring)
• Cardiac evaluation (ECG, 2D echocardiography) if anthracycline-based regimens are planned
• CT chest/abdomen/pelvis as an alternative staging tool where PET-CT is unavailable
• Anaesthesia fitness assessment including pulmonary function tests (for open surgery candidates)
• CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:
• Uncontrolled coagulopathy or active anticoagulation (relative contraindication to surgery; requires bridging protocol)
• Severe cardiopulmonary comorbidity precluding general anaesthesia (palliative/radiation-only approach considered)
• Active autoimmune disease on systemic immunosuppressants (relative contraindication to checkpoint inhibitor therapy)
• Prior pelvic irradiation (limits re-irradiation options; requires dosimetric review)
• BMI >50 kg/m² (significantly increases anaesthetic and surgical risk; requires multidisciplinary pre-optimization)
Procedure
SURGICAL APPROACHES:
1. Robotic-Assisted Laparoscopic Hysterectomy (da Vinci Si/Xi System): The preferred modality for most Stage I–II cases at high-volume cancer centres. Offers 3D magnification, wristed instrument precision, and superior access in the deep pelvis — critical for obese patients (BMI >35) who comprise a disproportionate share of endometrial cancer cases. Paired with ICG-based sentinel lymph node mapping (RELSN procedure), robotic surgery achieves equivalent oncologic clearance to open surgery with significantly shorter hospitalization (2–3 days), faster return to activity, and lower blood loss (<100 mL average).
2. Total Laparoscopic Hysterectomy (TLH) with BSO and SLN Biopsy: A cost-effective minimally invasive alternative to robotic surgery; widely performed at India's top oncology centres. Uses ICG fluorescence or technetium-99m radiocolloid ± blue dye for sentinel node identification. Avoids the morbidity of complete systematic pelvic lymphadenectomy in appropriately selected patients.
3. Open (Laparotomy) Radical Hysterectomy: Reserved for Stage III disease with parametrial/bladder/bowel involvement, large uterine sarcomas, or cases requiring en bloc resection of adjacent structures. Wertheim's radical hysterectomy (Type III) with pelvic and para-aortic lymphadenectomy is the benchmark for locally advanced disease.
4. Fertility-Sparing Management: For FIGO Stage IA Grade 1 endometrioid carcinoma in women <45 years who desire future fertility — megestrol acetate (160 mg/day) or medroxyprogesterone acetate (500 mg/day) combined with a levonorgestrel-releasing IUD, with mandatory hysteroscopic biopsy reassessment at 3 and 6 months. Complete response rates of 55–75% reported; definitive hysterectomy recommended after childbearing is complete.
RADIATION THERAPY:
5. Vaginal Brachytherapy (VBT): High-dose-rate (HDR) intracavitary brachytherapy targeting the vaginal vault — the standard adjuvant for intermediate-risk Stage I disease (PORTEC-2 trial evidence). Delivered in 3–5 outpatient fractions over 1–2 weeks. Highly effective with minimal bowel and bladder toxicity compared to external beam radiation.
6. External Beam Radiation Therapy (EBRT) — IMRT/VMAT: Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) to the pelvis is used for high-intermediate and high-risk disease. Pelvic IMRT significantly reduces gastrointestinal toxicity compared to conventional 4-field box technique. Stereotactic Body Radiation Therapy (SBRT) is increasingly used for oligometastatic disease or nodal recurrences.
SYSTEMIC THERAPY:
7. Carboplatin + Paclitaxel (CP Doublet): The global first-line chemotherapy backbone for Stage III–IV disease and high-grade histology (serous, clear cell, carcinosarcoma). Administered in 6 cycles every 21 days; response rates of 40–60% in advanced disease.
8. Pembrolizumab + Lenvatinib (Keytruda + Lenvima): FDA/EMA-approved second-line combination for advanced MMR-proficient endometrial carcinoma (KEYNOTE-775/Study 309). Objective response rate ~32%; median PFS 7.2 months vs. 3.8 months for chemotherapy alone — a paradigm shift in recurrent disease management.
9. Pembrolizumab + Carboplatin/Paclitaxel: First-line addition of pembrolizumab for dMMR/MSI-H tumors (KEYNOTE-868/NRG GY018 data). Dramatically improves PFS in dMMR disease (HR 0.30) and confers benefit even in pMMR tumors (HR 0.54). Now incorporated into NCCN Category 1 recommendations.
10. Dostarlimab (Jemperli): Anti-PD-1 monoclonal antibody approved for dMMR recurrent/advanced endometrial carcinoma. Used as monotherapy or combined with carboplatin/paclitaxel (RUBY trial).
11. Hormone Therapy: Progestins (megestrol, medroxyprogesterone), aromatase inhibitors (letrozole), or tamoxifen for ER/PR-positive low-grade recurrent disease — particularly in patients unfit for aggressive systemic therapy. Response rates 15–30%; useful for disease stabilization.
12. HER2-Targeted Therapy: Trastuzumab added to carboplatin/paclitaxel for HER2-overexpressing uterine serous carcinoma (NRG-GY008 data) — a biomarker-driven approach requiring HER2 IHC/FISH testing at diagnosis.
EMERGING & ADVANCED TECHNOLOGIES:
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Under investigation for Stage IV disease with peritoneal metastasis in specialized centres.
• Stereotactic Radiosurgery (Gamma Knife/CyberKnife): For brain metastases in advanced disease.
• NGS-guided tumor-agnostic therapies: Larotrectinib for NTRK fusion-positive tumors; entrectinib as an alternative.
Cost of Uterine Cancer Treatment: India vs. UAE
The cost of uterine cancer treatment varies substantially based on FIGO stage, chosen modality (minimally invasive surgery alone vs. combined chemoradiation), histologic subtype, and the need for advanced molecular testing or immunotherapy. India offers the same evidence-based surgical and oncologic protocols — including robotic surgery, ICG sentinel node mapping, and immunotherapy — at 40–60% lower cost than the UAE, owing to lower infrastructure overheads and volume-driven efficiencies at leading cancer hospitals. The UAE offers premium facility standards, shorter waiting times, and geographic proximity for patients from the GCC, Africa, and Europe, with all treatment delivered by internationally trained gynecologic oncologists at JCI- and DHA-accredited centres. Both destinations significantly undercut comparable treatment costs in the UK (£25,000–£60,000+) or the United States ($40,000–$120,000+).
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $18,000 | ~50% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $9,000 – $35,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & VIRTUAL CONSULTATION (Week 1–2 before travel):
• Submit medical records, biopsy reports, imaging (MRI/PET-CT), and pathology slides to GAF Healthcare's assigned gynecologic oncologist via secure online portal.
• Receive a detailed multidisciplinary tumor board (MDT) opinion within 48–72 hours, including recommended surgical approach, molecular testing requirements, and estimated treatment timeline.
• GAF Healthcare initiates e-Medical Visa application (India) or coordinates tourist/medical entry visa (UAE) based on patient nationality.
• Pre-operative blood work, cardiac clearance, and anaesthesia assessment forms are sent to local physician for preliminary completion.
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in destination):
• Airport pickup by dedicated GAF Healthcare coordinator; check-in at hospital-affiliated or partner accommodation.
• Day 1: Hospital registration, repeat or confirmatory diagnostics if slides/images require local pathology review (routine at JCI-accredited centres for quality assurance).
• Day 2: Anaesthesia pre-assessment, bowel preparation instructions, DVT prophylaxis education, and consent process with operating gynecologic oncologist.
• Day 3: Final pre-operative fasting, IV access established, prophylactic LMWH administered if indicated.
PHASE 3 — SURGICAL PROCEDURE (Day 3–4):
• Robotic or laparoscopic hysterectomy: Operating time 2–4 hours under general anaesthesia. ICG fluorescence injected at the cervix for SLN mapping; robotic arms docked; TH-BSO + SLN dissection completed. Frozen section analysis of sentinel nodes performed intraoperatively to guide real-time decision-making on lymphadenectomy extent.
• Open radical hysterectomy (if indicated): 3–5 hours; drain placement; 24-hour ICU monitoring post-operatively.
• Patient transferred to recovery room, then surgical ward. Catheter in situ for 24–48 hours. Sequential compression devices applied immediately post-operatively for DVT prophylaxis.
PHASE 4 — INPATIENT RECOVERY (Days 4–8 for MIS; Days 5–10 for open surgery):
• Day 1 post-op: Early ambulation (4–6 hours post-surgery for robotic cases), liquid diet initiated, IV analgesia transitioned to oral medications.
• Day 2–3 post-op: Diet advanced, physiotherapy commenced, drain removed if output <50 mL/24 hours.
• Pathology of surgical specimen typically reported within 5–7 working days: confirms FIGO stage, lymph node status, lymphovascular space invasion (LVSI), and molecular subtype for final adjuvant therapy planning.
• Discharge with wound care instructions, LMWH prescription, VTE prophylaxis plan, and follow-up appointment scheduled.
PHASE 5 — ADJUVANT THERAPY PLANNING & INITIATION (Weeks 2–6 in destination, if applicable):
• MDT convenes on final pathology; risk stratification determines adjuvant requirement.
• Low-risk (Stage IA G1–2, no LVSI): Observation only; patient may travel home after wound check at Day 14.
• Intermediate-risk: Vaginal brachytherapy initiated approximately 4–6 weeks post-surgery (3–5 fractions over 1–2 weeks as outpatient).
• High-risk/Advanced: Concurrent chemoradiation or carboplatin/paclitaxel initiated; patient extends stay or returns in cycles.
• For pure systemic therapy patients: First 1–2 cycles supervised in destination country; subsequent cycles may be arranged with local oncologist in home country with GAF Healthcare coordinating treatment summary and protocol documentation.
PHASE 6 — DISCHARGE, FIT-TO-FLY ASSESSMENT & FOLLOW-UP:
• Formal fit-to-fly assessment by treating physician at Day 21 (MIS) or Day 35–42 (open/chemoradiation).
• DVT risk stratified using Caprini Score; extended LMWH prophylaxis prescribed for high-risk flyers (flights >4 hours).
• Compression stockings and ambulation instructions provided for flight.
• GAF Healthcare transfers complete discharge summary, operative notes, pathology reports, and radiation dosimetry records (where applicable) to patient's home oncologist.
• Surveillance schedule: clinical examination + CA-125 (if elevated at baseline) every 3 months for 2 years, then every 6 months to year 5; MRI pelvis annually or as clinically indicated.
Risks & Considerations
Uterine cancer treatment carries procedure-specific and systemic risks that must be discussed thoroughly with the treating gynecologic oncologist. Surgical risks include intraoperative hemorrhage (conversion to open surgery in <3% of robotic cases), ureteral or bladder injury (<1–2% incidence, higher in locally advanced disease), bowel injury, and venous thromboembolism (DVT/PE — the leading cause of post-operative mortality in gynecologic oncology, mitigated by LMWH prophylaxis and early ambulation). Lymphedema of the lower limbs affects 5–15% of patients who undergo systematic pelvic lymphadenectomy; risk is substantially lower with sentinel node biopsy alone. Vaginal vault dehiscence is a rare but serious complication of post-surgical vaginal brachytherapy, occurring in <1–3% of cases. Radiation-related late toxicities include radiation proctitis, cystitis, and small bowel obstruction — incidence markedly reduced with IMRT/VMAT vs. conventional radiation. Chemotherapy toxicities with carboplatin/paclitaxel include peripheral neuropathy (dose-limiting in 20–30% of patients), myelosuppression, alopecia, and hypersensitivity reactions. Immune checkpoint inhibitors (pembrolizumab, dostarlimab) carry risk of immune-related adverse events (irAEs) including colitis, pneumonitis, hepatitis, endocrinopathies (hypothyroidism, adrenal insufficiency), and, rarely, severe grade 3–4 reactions requiring high-dose systemic corticosteroids or permanent drug discontinuation. Patients with pre-existing autoimmune conditions require specialized risk-benefit counseling before initiating immunotherapy. For international patients specifically, the risk of long-haul air travel post-operatively is significant — all patients must receive formal fit-to-fly clearance and individualized VTE prophylaxis plans before boarding. Premature travel without clearance substantially elevates pulmonary embolism risk. GAF Healthcare's case managers coordinate closely with the treating team to ensure no patient is discharged to travel without written medical clearance documentation.
Top Hospitals for Uterine Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Uterine Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Uterine Cancer Treatment
The total cost of uterine cancer treatment depends on the stage of disease, the chosen modality, and whether adjuvant therapy (radiation, chemotherapy, or immunotherapy) is required. In India, a minimally invasive robotic hysterectomy with sentinel lymph node biopsy for early-stage disease typically costs USD 4,000–8,000, while a comprehensive treatment package for advanced-stage disease — including open radical hysterectomy, IMRT radiation, and multiple cycles of carboplatin/paclitaxel chemotherapy — can range from USD 12,000–18,000. In the UAE, the equivalent early-stage robotic surgical package is priced at approximately USD 9,000–15,000, and advanced multimodal treatment costs USD 22,000–35,000. Both destinations offer costs that are 50–75% below equivalent treatment in the United Kingdom or the United States. Importantly, the oncologic protocols — surgical techniques (robotic, ICG sentinel node mapping), radiation technology (IMRT/VMAT, HDR brachytherapy), and drug regimens (including pembrolizumab immunotherapy for eligible patients) — are equivalent in quality at JCI-accredited partner hospitals in both countries. GAF Healthcare provides a detailed, itemized cost estimate based on your specific diagnosis and treatment plan before you commit to travel.
The minimum safe stay before international air travel depends on the treatment modality received. Patients who undergo robotic-assisted or laparoscopic hysterectomy (minimally invasive surgery) without adjuvant therapy are typically cleared for long-haul flights at 21 days (3 weeks) post-operatively, provided wound healing is confirmed and DVT risk assessment is satisfactory. Patients who undergo open radical hysterectomy require a minimum of 4–5 weeks before flying. If adjuvant vaginal brachytherapy is required (3–5 outpatient fractions over 1–2 weeks), the total stay extends to approximately 5–6 weeks from the date of surgery. Patients requiring concurrent external beam chemoradiation must typically remain for 8–10 weeks in-country to complete the treatment course before receiving fit-to-fly clearance. All patients receive a formal written Fit-to-Fly certificate from the treating oncologist, and those assessed as high DVT risk (Caprini Score ≥5, or flights >4 hours) are prescribed extended low-molecular-weight heparin injections and compression stockings for the journey. GAF Healthcare's case manager builds your itinerary around these clinical milestones to ensure no patient travels before it is medically safe to do so.
Success rates for uterine cancer treatment are highly stage- and histology-dependent. Five-year overall survival rates are as follows: FIGO Stage I (disease confined to the uterine body) — approximately 90–95% with surgical treatment alone or surgery plus vaginal brachytherapy for intermediate-risk cases; FIGO Stage II (cervical stromal involvement) — approximately 70–75% with combined surgery and adjuvant radiotherapy; FIGO Stage III (regional spread to adnexa, vagina, parametria, or lymph nodes) — approximately 40–55% with multimodal treatment including surgery, EBRT, and chemotherapy; FIGO Stage IVB (distant metastasis) — approximately 15–20% at 5 years, with treatment focused on systemic chemotherapy and immunotherapy for eligible patients. The introduction of pembrolizumab (anti-PD-1 immunotherapy) for mismatch repair-deficient (dMMR/MSI-H) tumors has significantly improved progression-free survival in advanced and recurrent disease, with KEYNOTE-868 data demonstrating a 70% reduction in the risk of disease progression or death in dMMR patients receiving first-line pembrolizumab plus chemotherapy. Molecular profiling at diagnosis (POLE, MMR, p53) is therefore now standard at all GAF Healthcare partner centres, as it directly determines both prognosis and eligibility for these high-efficacy immunotherapy regimens. The gynecologic oncology teams at GAF Healthcare's partner hospitals manage hundreds of uterine cancer cases annually, with surgical complication rates and oncologic outcomes benchmarked against international standards.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated non-medical concierge infrastructure designed to eliminate logistical barriers for international oncology patients.
INDIA LOGISTICS:
• e-Medical Visa Assistance: GAF Healthcare's dedicated visa team guides patients and one accompanying attendant through the Indian e-Medical Visa application (available to citizens of 156+ countries), which permits a 60-day stay, extendable up to 180 days — critical for patients requiring adjuvant chemoradiation after surgery. Visa approval typically within 72–96 hours of application. Attendants apply simultaneously for the e-Medical Attendant Visa.
• Hospital Empanelment: Partner hospitals include JCI-accredited and NABH-certified institutions in Delhi NCR (Medanta, Artemis, Fortis Gurugram), Mumbai (Kokilaben Dhirubhai Ambani, Tata Memorial), Chennai (Apollo Proton Cancer Centre, MIOT), and Bengaluru (Manipal Comprehensive Cancer Centre, HCG).
• Airport Transfers: Private ambulance-equipped or executive vehicle transfers from all major international airports (IGI Delhi, CSIA Mumbai, MAA Chennai) directly to the partner hospital, coordinated 24/7.
• Accommodation: GAF Healthcare partners with hospital guesthouses and serviced apartments within 0.5–2 km of the treating facility for the patient's attendant, with hospital meal plan tie-ups and laundry services.
• Interpreter Services: Dedicated multilingual medical interpreters available for Arabic, Russian, Swahili, French, Bangla, and Pashto speakers; present during all consultations, consent processes, and discharge briefings.
UAE LOGISTICS:
• Visa Facilitation: Citizens of 49+ countries (including GCC nationals) enjoy visa-free access to the UAE. Patients from other nationalities receive visa-on-arrival (30 days, extendable) or a medical treatment visa (up to 90 days) arranged through GAF Healthcare's UAE partner coordinator in collaboration with the treating hospital.
• Hospital Empanelment: JCI-accredited and DHA/DOH-licensed oncology centres including Cleveland Clinic Abu Dhabi (Oncology Institute), Mediclinic City Hospital Dubai, American Hospital Dubai, and King's College Hospital London — Dubai.
• Airport Transfers: Private executive transfers from Dubai International Airport (DXB) or Abu Dhabi International Airport (AUH) to the hospital and patient accommodation.
• Accommodation: Selection of hospital-affiliated hotel apartments, luxury serviced residences, or standard medical tourism apartments for attendants, within proximity to treatment centre; GAF Healthcare negotiates extended-stay rates.
• Translation & Cultural Support: Arabic-speaking patient navigators available on-site at UAE facilities; additional interpreters for Urdu, French, Russian, and Amharic.
ALL DESTINATIONS — CROSS-CUTTING SERVICES:
• 24/7 dedicated case manager assigned from initial inquiry through last day of stay
• Second opinion coordination before final treatment decision
• Digital medical record transfer to home-country oncologist upon discharge
• Telemedicine follow-up appointments with treating surgeon at 2 weeks, 6 weeks, and 3 months post-departure
• Travel insurance guidance and liaison with insurers requiring pre-authorisation letters
Patients Also Explore
Other treatments commonly sought by patients considering Uterine Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology